CellaVision
ISIN: SE0000683484 | Ticker: CEVI | LEI: 529900IUBZBZ0HXFJ114
Country: Sweden
CellaVision is an innovative, global medical technology company that develops and sells systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and support effective workflows and skills development within and between hospitals.
The company has expertise in image analysis, artificial intelligence and automated microscopy. Sales are via global distributors, with support from the parent company in Lund and by the market support organizations in the US, Canada, China, Sweden, Japan, United Arab Emirates, South Korea, Australia, France, Germany, Brazil, Great Britain, Mexico, India, Thailand, Spain, Italy, and Russia. In 2020, sales were SEK 471.4 million. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list.
1994
Served areaWorldwide
HeadquartersMobilvägen 12, 22362 Lund – Sweden
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 668,025,000.00 | 825,212,000.00 | 891,748,000.00 |
| Noncurrent Assets | N/A | 369,959,000.00 | 460,493,000.00 | 514,604,000.00 |
| Land And Buildings | N/A | 35,359,000.00 | 62,389,000.00 | 86,813,000.00 |
| Goodwill | N/A | 111,972,000.00 | 114,085,000.00 | 124,141,000.00 |
| Intangible Assets Under Development | N/A | 94,269,000.00 | 126,275,000.00 | 162,709,000.00 |
| Current Assets | N/A | 298,066,000.00 | 364,719,000.00 | 377,144,000.00 |
| Inventories | N/A | 83,660,000.00 | 115,088,000.00 | 142,571,000.00 |
| Trade And Other Current Receivables | N/A | 112,144,000.00 | 119,346,000.00 | 126,520,000.00 |
| Current Trade Receivables | N/A | 71,030,000.00 | 89,736,000.00 | 97,630,000.00 |
| Other Current Receivables | N/A | 23,479,000.00 | 20,076,000.00 | 15,079,000.00 |
| Current Tax Assets Current | N/A | 11,698,000.00 | 4,395,000.00 | 7,113,000.00 |
| Cash and cash equivalents | 102,312,000.00 | 102,262,000.00 | 130,286,000.00 | 108,053,000.00 |
| Equity And Liabilities | N/A | 668,025,000.00 | 825,212,000.00 | 891,748,000.00 |
| Equity | 348,373,000.00 | 429,617,000.00 | 543,280,000.00 | 641,628,000.00 |
| Issued Capital | N/A | 3,578,000.00 | 3,578,000.00 | 3,578,000.00 |
| Retained Earnings | N/A | 429,835,000.00 | 537,285,000.00 | 607,917,000.00 |
| Other Reserves | N/A | -14,596,000.00 | -8,383,000.00 | 19,333,000.00 |
| Additional Paidin Capital | N/A | 10,800,000.00 | 10,800,000.00 | 10,800,000.00 |
| Equity Attributable To Owners Of Parent | N/A | 429,617,000.00 | 543,280,000.00 | 641,628,000.00 |
| Noncurrent Liabilities | N/A | 134,263,000.00 | 147,432,000.00 | 117,029,000.00 |
| Noncurrent Provisions | N/A | 3,982,000.00 | 3,636,000.00 | 3,740,000.00 |
| Deferred Tax Liabilities | N/A | 43,377,000.00 | 47,951,000.00 | 52,925,000.00 |
| Longterm Borrowings | N/A | 86,904,000.00 | 95,845,000.00 | 60,364,000.00 |
| Current Liabilities | N/A | 104,145,000.00 | 134,500,000.00 | 133,092,000.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 20,865,000.00 | 44,861,000.00 | 47,864,000.00 |
| Current Accruals And Current Deferred Income Including Current Contract Liabilities | N/A | N/A | 39,898,000.00 | 37,825,000.00 |
| Other Current Payables | N/A | 1,973,000.00 | 4,277,000.00 | 2,372,000.00 |
| Current Tax Liabilities Current | N/A | 187,000.00 | 2,205,000.00 | 58,000.00 |
| Line item in (sek) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 471,443,000.00 | 565,552,000.00 | 639,340,000.00 |
| Profit Loss From Operating Activities | 110,273,000.00 | 162,733,000.00 | 158,266,000.00 |
| Profit Loss Before Tax | 112,228,000.00 | 158,297,000.00 | 148,429,000.00 |
| Income Tax Expense Continuing Operations | 22,748,000.00 | 32,958,000.00 | 30,094,000.00 |
| Profit (loss) | 89,480,000.00 | 125,339,000.00 | 118,335,000.00 |
| Line item in (sek) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | 89,480,000.00 | 125,339,000.00 | 118,335,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -29,752,000.00 | -31,058,000.00 | -26,323,000.00 |
| Other Adjustments For Noncash Items | N/A | 15,630,000.00 | 42,013,000.00 | 44,788,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 2,546,000.00 | 1,866,000.00 | 2,340,000.00 |
| Interest Received Classified As Operating Activities | N/A | 416,000.00 | 60,000.00 | 200,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 71,124,000.00 | 159,717,000.00 | 137,285,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 1,269,000.00 | 0.00 | N/A |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 8,069,000.00 | 13,716,000.00 | 23,482,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 64,000.00 | 31,802,000.00 | 201,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -34,959,000.00 | -84,339,000.00 | -70,014,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 3,041,000.00 | 20,705,000.00 | 0.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 28,721,000.00 | 40,298,000.00 | 31,935,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 9,537,000.00 | 10,994,000.00 | 10,772,000.00 |
| Dividends Paid Classified As Financing Activities | N/A | 0.00 | 17,889,000.00 | 47,703,000.00 |
| Cash Flows From Used In Financing Activities | N/A | -35,218,000.00 | -48,475,000.00 | -90,410,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 948,000.00 | 26,903,000.00 | -23,139,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -998,000.00 | 1,122,000.00 | 906,000.00 |
| Cash and cash equivalents | 102,312,000.00 | 102,262,000.00 | 130,286,000.00 | 108,053,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 07.02.23 | Christer Fåhraeus | Other | Buy | SEK 63,420.00 |
| 07.11.22 | Simon Ostergaard | Other | Buy | SEK 54,441.00 |
| 07.11.22 | Simon Ostergaard | Other | Buy | SEK 51,562.50 |
| 07.11.22 | Simon Ostergaard | Other | Buy | SEK 51,250.00 |
| 07.11.22 | Simon Ostergaard | Other | Buy | SEK 39,975.00 |
| 07.11.22 | Simon Ostergaard | Other | Buy | SEK 32,913.00 |
| 07.11.22 | Simon Ostergaard | Other | Buy | SEK 22,770.00 |
| 07.11.22 | Simon Ostergaard | Other | Buy | SEK 20,650.00 |
| 07.11.22 | Simon Ostergaard | Other | Buy | SEK 10,350.00 |
| 07.11.22 | Simon Ostergaard | Other | Buy | SEK 7,790.00 |
SE0000683484
LEI529900IUBZBZ0HXFJ114
SectorHealth Care Equipment & Services
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.